Watches created for a cause often face a difficult balancing act. It is all too easy for a charity piece to lean too heavily on good intentions while compromising on design, or conversely, to relegate its mission to a footnote on a caseback. For the second year running, Worn & Wound has teamed up with adventure-ready microbrand BOLDR to prove that a timepiece can be both a highly capable, design-forward tool watch and a powerful vehicle for fundraising.
Priced at an incredibly accessible $399, the brand new Worn & Wound x BOLDR Conquer 2026 Limited Edition Chronograph arrives with year two of the same vital mission, but with a radical, high-contrast aesthetic overhaul that demands attention.
A Saturated Aesthetic Built for a Cause
While the technical foundation of the watch carries over from its 2025 predecessor, the visual impact of the 2026 edition is entirely new. The defining feature of this release is the middle of the case, which has been finished in a deeply saturated, vibrant pink Cerakote. This loud, intentional choice is paired beautifully with a brushed silver 12-hour bezel and a glossy black dial sporting twin silver sub-registers.
* Mid-Case Finish: Saturated Pink Cerakote
* Bezel Type: Brushed Silver 12-Hour Scale
* Dial Style: Glossy Black with Twin Silver Sub-Registers
The choice of color isn’t just about making a statement on the wrist—it directly supports the team riding in the 2026 Ride to Conquer Cancer. For every single watch sold, $80 goes directly to The Princess Margaret Cancer Foundation through the team’s “Can’t Stop, Won’t Stop” initiative. It is a brilliant example of intentional design where the color palette directly mirrors the heart of the cause.
“The color choices are bold on purpose. It’s an unmissable nod to the collective fight against cancer, wrapped up in a package that watch enthusiasts can genuinely appreciate for its design merit.”
The Resilient Titanium Foundation
Beneath the eye-catching Cerakote finish lies BOLDR’s famously rugged Venture architecture. The watch features a 41mm titanium case that strikes the perfect balance between extreme lightweight comfort and structural resilience.
With a thickness of 12.5mm and a compact 46mm lug-to-lug distance, the watch sits beautifully on a wide variety of wrists, staying out of the way whether you are cycling or navigating a daily commute.
Inside beats the ubiquitous Japanese SII VK64 mechaquartz chronograph movement. Loved by microbrands and collectors alike, this hybrid engine provides the unflinching accuracy of a quartz timekeeper with the tactile, satisfying click and instant mechanical sweep-back of a traditional mechanical chronograph.
The watch doesn’t skimp on real-world tool capabilities either. It boasts a flat sapphire crystal coated with an anti-reflective layer, a custom signed screw-down crown, and a robust 200 meters of water resistance.
Flip the watch over, and a screw-down display caseback proudly showcases the movement alongside the team’s signature “Can’t Stop, Won’t Stop” octagon logo.
The Complete Team Kit
True to the spirit of the Ride to Conquer Cancer, the watch does not ship in a standard box. Instead, Worn & Wound and BOLDR have curated a complete team kit for the collector. Each watch includes a custom blue and pink nylon StrapHabit x Worn & Wound Team Strap, alongside an exclusive BOLDR x Worn & Wound Team Cycling Cap that cannot be purchased separately.
Technical Specifications
| Dimension/Feature | Specification |
| Case Material | 41mm Titanium (with Pink Cerakote Mid-Case) |
| Thickness / Lug-to-Lug | 12.5mm / 46mm |
| Movement | Japanese SII VK64 Mechaquartz Chronograph |
| Water Resistance | 200m (20 ATM) |
| Crystal | Flat Sapphire with Anti-Reflective Coating |
| Charity Contribution | $80 per watch to Princess Margaret Cancer Foundation |
Limited to just 200 pieces worldwide and scheduled to ship in mid-August 2026, the Worn & Wound x BOLDR Conquer 2026 is an exceptional offering. For $399, it provides collectors with a highly stylized, rugged titanium chronograph, while making a tangible, meaningful impact in the global fight against cancer.
